Ftc report patent thickets biologics humira?

Short answer: there isn’t a single FTC report titled something like “Patent Thickets in Biologics Humira.” The FTC has published reports and materials that discuss related issues (patent thickets, evergreening, and pay-for-delay in pharma), and Humira is often cited as an example in discussions of how a biologic can obtain a dense patent portfolio to delay biosimilar competition.

What the FTC has covered (relevant to your topic)
- Pay-for-delay and patent settlements: FTC has produced staff reports and analysis on settlements between brand-name drug firms and generics/biosimilars that delay entry. These documents discuss how settlements can keep competition out and extend market exclusivity.
- Competition in biopharmaceuticals: The FTC (often with DOJ) has explored how patent strategies in biologics affect competition and access, including the use of multiple patents (a “thicket”) to block or slow biosimilars.
- Humira as a case study: Humira is frequently cited in legal and policy discussions as an example of how a biologic can build a broad patent portfolio and litigate or settle with biosimilar challengers to extend exclusivity.

If you’d like, I can:
- Give you a concise summary of what a patent thicket is, and how it can affect biosimilars like Humira.
- List specific FTC sources (with titles and years) and brief summaries.
- Provide a quick overview of Humira’s patent landscape and how biosimilar competition unfolded.

Would you like a short sourced summary or links to particular FTC materials?